anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
NEW MATERIAL:A complex labeled with technetium-99m of a compound expressed by the formula (n is an integer 1-3; R is H or NH2-CO-). EXAMPLE:Carbamyl cysteine complex labeled with technetium-99m. USE:A radioactive diagnostic agent for cancer, capable of exhibiting high accmulation for cancers, high clearance in blood and capable of detecting the cancerous site in a short time after the administration. The cancerous site is diagnosed by picking up images with a scintillation scanner, scintillation camera or measuring the radioactivity. PREPARATION:A compound expressed by the formula or a salt thereof and a pertechnetic acid reducing agent are mixed with a suitable solvent to give a composition useful for preparing a radioactive diagnostic agent. A water-soluble reducing agent, preferably stannous salt is used as the pertechnetic acid reducing agent. The resultant above-mentioned composition is then brought into contact with a solution of a pertechnetate-technetium-99m to afford the aimed novel complex labeled with technetium-99m.
Fibroblasts are key regulators of inflammation, fibrosis, and cancer. Targeting their activation in these complex diseases has emerged as a novel strategy to restore tissue homeostasis. Here, we present a multidisciplinary lead discovery approach to identify and optimize small molecule inhibitors of pathogenic fibroblast activation. The study encompasses medicinal chemistry, molecular phenotyping assays, chemoproteomics, bulk RNA-sequencing analysis, target validation experiments, and chemical absorption, distribution, metabolism, excretion and toxicity (ADMET)/pharmacokinetic (PK)/in vivo evaluation. The parallel synthesis employed for the production of the new benzamide derivatives enabled us to a) pinpoint key structural elements of the scaffold that provide potent fibroblast-deactivating effects in cells, b) discriminate atoms or groups that favor or disfavor a desirable ADMET profile, and c) identify metabolic "hot spots". Furthermore, we report the discovery of the first-in-class inhibitor leads for hypoxia up-regulated protein 1 (HYOU1), a member of the heat shock protein 70 (HSP70) family often associated with cellular stress responses, particularly under hypoxic conditions. Targeting HYOU1 may therefore represent a potentially novel strategy to modulate fibroblast activation and treat chronic inflammatory and fibrotic disorders.
PURPOSE:To obtain ultrafine particles of an org. compound, especially, water-insoluble medicine, by evaporating the org. compound under heating in inert gas within a vacuum container and coagulating fine particles generated by collision on a cooled recovery means. CONSTITUTION:An org. compound (containing a high-molecular compound) having vapor pressure of a definite value or more is put in a heating apparatus 2 and, after a vacuum container 1 is brought to a predetermined vacuum degree, inert gas is introduced into the container 1 to adjust the pressure thereof to a definite value and the heating of the org. compound is started. The molecules of the org. compound evaporated by heating are scattered and collide with each other to be formed into ultrafine partcles which are, in turn, coagulated on a coolled aluminum foil 7 to be accumulated thereon. As mentioned above, by regulating the pressure of the inert gas, ultrafine particles with a particle size of about 500Angstrom -4mum can be obtained. If the obtained fine particles are prepared from water-insoluble medicine, the stable aqueous dispersion thereof can be obtained and, therefore, an injection liquid can be obtained. Further, said particles can be expected as the material of an org. semiconductor or a sensor.
Neurotrauma in limbs can induce sustained neuroinflammation, resulting in persistent disruption of nerve tissue architecture and retardation of axon regrowth. Despite macrophage-mediated inflammation promoting the removal of necrotic neural components and stimulating neo-vessel ingrowth, detrimental shifts in macrophage phenotype exacerbate nerve degeneration. Herein, we find that peripheral nerve injuries (PNIs) result in abundant secreted frizzled-related protein 1 (sFRP1) expression, particularly by Schwann cells (SCs). Heat shock protein 90 (HSP90) in macrophages recognizes sFRP1 and triggers a dysregulated secretion of inflammatory mediators. Single-cell atlas of human injured peripheral nerves reveals the appearance of sFRP1-expressing SCs with mesenchymal traits and macrophages with a proinflammatory genetic profile. Deletion of either SC-specific sFRP1 or macrophage-specific HSP90 alleviates neuroinflammation and prevents the progression of nerve degeneration. Together, our findings implicate the response of macrophages to SC-derived sFRP1 in exacerbating nerve damage following PNIs.
Twenty patients who developed thrombocytopenia after a chemotherapy course will receive i.v. infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen, during the following 4 chemotherapy courses.
The human gut microbiota is increasingly recognized as a pivotal factor in diabetes management, playing a significant role in the body's response to treatment. However, it is important to understand that long-term usage of medicines like metformin and other diabetic treatments can result in problems, gastrointestinal discomfort, and dysbiosis of the gut flora. Advanced sequencing technologies have improved our understanding of the gut microbiome's role in diabetes, uncovering complex interactions between microbial composition and metabolic health. We explore how the gut microbiota affects glucose metabolism and insulin sensitivity by examining a variety of -omics data, including genomics, transcriptomics, epigenomics, proteomics, metabolomics, and metagenomics. Machine learning algorithms and genome-scale modeling are now being applied to find microbiological biomarkers associated with diabetes risk, predicted disease progression, and guide customized therapy. This study holds promise for specialized diabetic therapy. Despite significant advances, some concerns remain unanswered, including understanding the complex relationship between diabetes etiology and gut microbiota, as well as developing user-friendly technological innovations. This mini-review explores the relationship between multiomics, precision medicine, and machine learning to improve our understanding of the gut microbiome's function in diabetes. In the era of precision medicine, the ultimate goal is to improve patient outcomes through personalized treatments.
Recurrent glioblastoma (rGBM) patients who are scheduled for surgery and expected to receive postoperative fractionated radiotherapy (RT) will be treated with pamiparib for 4 days prior to surgical resection. Patients who proceed to Phase 2 will receive pamiparib administered orally BID continuously in combination with 6-7 weeks of radiation therapy and pamiparib in combination with TMZ in the maintenance phase.
Extubation is a crucial step in the weaning process of critically ill mechanically ventilated patients. Some patients may develop postextubation respiratory failure that may lead to the need for re-intubation, which is associated with increased morbidity and mortality. This review comprehensively explores postextubation respiratory support strategies, focusing on the efficacy of high-flow nasal cannula (HFNC) oxygen therapy and noninvasive ventilation (NIV) in reducing re-intubation rates among various patient populations. HFNC improves oxygenation and reduces the work of breathing. However, its effectiveness in preventing re-intubation varies according to the patient's characteristics and the predefined risk for re-intubation. NIV, alternatively, appears to provide substantial advantages in reducing the rates of re-intubation and respiratory failure, especially in patients with obesity and patients with hypercapnia. Therefore, the indiscriminate application of these support strategies without consideration of individual patient characteristics may not improve outcomes, highlighting the need for careful patient selection and tailored therapeutic strategies based on specific risk factors and clinical conditions. By aligning postextubation respiratory support strategies with patient-specific needs, we may improve the success rates of extubation, enhance overall recovery, and reduce the burden of reintubations in the intensive care setting.
The invention comprises steroids of the formula <FORM:0996308/C2/1> (wherein R1 is OH or Oacyl, and R2 is a saturate or unsaturated hydrocarbon radical of at most 4 carbon atoms, or R1 and R2 together are a keto group) and their preparation by splitting off the 3-substituent from a corresponding 3-halo or -sulphonyloxy steroid (wherein the the sulphonyloxy group is an aliphatic, aromatic or araliphatic hydrocarbon-sulphonyloxy group) by reduction.  The product or the starting material, if 17-ol, may be oxidized to the 17-one, which may be reacted with a hydrocarbon metal compound to give the 17a -hydrocarbon-17b -ol. In this, an alkynyl group may be reduced to an alkenyl or alkyl group. 17-ols may be esterified, and 17-esters hydrolysed. Examples are given.  The preparation of the starting materials is described in Specification 996,309.  The 3-unsubstituted steroids of the invention, which are stated to have progestative, gonad-inhibiting and estrogenic activity, may be made up into pharmaceutical compositions with inert carriers.
R/R DLBCL patients were treated with 2 cycles of CAGM regimen including chidamide, azacitidine, obinutuzumab and liposomal mitoxantrone followed by imaging examination. Patients achieved CR/PR were exposed to ASCT/CAR-T therapy or additional 4 cycles of CAGM regimen in patients ineligible for ASCT/CAR-T therapy; whereas, patients with SD/PD were withdrawn from this study.
<P>PROBLEM TO BE SOLVED: To provide a convenient image-photographing system for medical use capable of storing item information regarding patients and photographing entered as reservation information and outputting a stored arbitrary items information to an output address.  <P>SOLUTION: Reservation information entered from an HIS (hospital information system) 30 contains specified data of item information. When processing input or output of the reservation information, a CPU (central processing unit) 11 first stores the specified data of the item information in corresponding information item contents of a reservation information file 161. An user then selects an information item to be outputted on a filing device 40, enters the selected information item from an input part 12, and turns on an output flag of the selected information item. When an item information output instruction from the input part 12 is detected, the specified data having the instructed reservation numbers are extracted from the information item contents whose output flags are turned on and are outputted on the filing device 40 via a communication control part 14 along with image information or additional information having the reservation number.  <P>COPYRIGHT: (C)2004,JPO
PURPOSE: Amyotrophic lateral sclerosis (ALS) is a progressive, ultimately fatal disease causing progressive muscular weakness. Most people living with ALS (plwALS) experience dysarthria, eventually becoming unable to communicate using natural speech. Many wish to use speech for as long as possible. Personalized automated speech recognition (ASR) model technology, such as Google's Project Relate, is argued to better recognize speech with dysarthria, supporting maintenance of understanding through real-time captioning. The objectives of this study are how plwALS and communication partners use Relate in everyday conversation over a period of up to 12 months and how it may change with any decline in speech over time.
METHOD: This study videoed interactions between three plwALS and communication partners. We assessed ASR caption accuracy and how well they preserved meaning. Conversation analysis was used to identify participants' own organizational practices in the accomplishment of interaction. Thematic analysis was used to understand better the participants' experiences of using ASR captions.
RESULTS: All plwALS reported lower-than-expected ASR accuracy when used in conversation and felt ASR captioning was only useful in certain contexts. All participants liked the concept of live captioning and were hopeful that future improvements to ASR accuracy may support their communication in everyday life.
CONCLUSIONS: Training is needed on best practices for customization and practical use of ASR technology and for the limitations of ASR in conversational settings. Support is needed for those less confident with technology and to reduce misplaced allocation of ownership of captioning errors, risking negative effects on psychological well-being.
There is a growing interest in the use of physical activity data in clinical studies, particularly in diseases that limit mobility in patients. High-frequency data collected with digital sensors are typically summarised into actigraphy features aggregated at epoch level (e.g., by minute). The statistical analysis of such volume of data is not straightforward. The general trend is to derive metrics, capturing specific aspects of physical activity, that condense (say) a week worth of data into a single numerical value. Here we propose to analyse the entire time-series data using Generalised Additive Models (GAMs). GAMs are semi-parametric models that allow inclusion of both parametric and non-parametric terms in the linear predictor. The latter are smooth terms (e.g., splines) and, in the context of actigraphy minute-by-minute data analysis, they can be used to assess daily patterns of physical activity. This in turn can be used to better understand changes over time in longitudinal studies as well as to compare treatment groups. We illustrate the application of GAMs in two clinical studies where actigraphy data was collected: a non-drug, single-arm study in patients with amyotrophic lateral sclerosis, and a physical-activity sub-study included in a phase 2b clinical trial in patients with chronic obstructive pulmonary disease.
The patient will be submitted to multimodal treatment, twice a week, for twelve weeks, totaling 24 face-to-face consultations lasting 40 minutes each. In the first session, the patient will be explained what is TMD, what is the correct placement of the tongue and teeth, influence of parafunctional and sleep habits in TMD signs and symptoms.Techniques of manual therapy and therapy by exercise. In general, extra-oral and intraoral massage, myofascial release in the cranio-cervical musculature, mobilization of the hyoid bone and may also receive unspecific joint mobilization. Will be mouth opening exercise will be also performed with the tongue on the palate, proprioceptive exercises with hyperboloid. In addition to these, additional exercises may be performed, according to the patient's need. The conducts will be adapted according to the needs of each patient. The use of post its may be indicated to help maintain the correct posture of the tongue and jaw, as well as sleep hygiene.
The NSS-2 BRIDGE is a battery operated and disposable percutaneous auricular nerve field stimulator (Innovative Health Solutions, Versailles, IN, USA), that was recently cleared by the FDA and assigned a Class II Risk Designation; a class which includes surgical drapes, pumps and power wheelchairs. The indication for the NSS-2 BRIDGE is for the treatment of clinical symptoms related to opioid consumption and opioid withdrawal.
The invention provides a stem cell preparation for treating diabetes mellitus. The stem cell preparation comprises: stem cells separated and extracted from human blood or tissues and organs and/or islet-like cells induced and differentiated from the stem cells and a cell preservation solution containing 0.5% of heparin calcium, wherein the cell content is 1*10<5> to 5*10<7>/ml. The invention also discloses a preparation method of the stem cell preparation. The method comprises the following steps: (1) separation and purification of the stem cell; (2) in vitro culture of the stem cells or in vitro induction and differentiation of the stem cells to form islet-like cells; (3) diluting the cell obtained in the step (2) by using the cell preservation solution to prepare a stem cell preparation; (4) quality detection of the stem cell preparation. The stem preparation is transplanted into the body and can be differentiated into insulin-secreting cells to secret insulin, and the blood sugar concentration of a person with diabetes is effectively reduced. Thus, a new way is provided for overcoming treatment of the diabetes dependent on the insulin and curing the diabetes once and for all.
Compsn. for preliminary treatment of acute and chronic myelogenic leukaemia in humans, who are later to receive treatment with cytotoxic agents (A), contains 3-fluoro-4-phenylhydratropic acid (I) or p-isobutylhydratropic acid (II) or their 1-8C alkyl esters or pharmaceutically acceptable salts. When treatment with several (A) is intended, a suitable regime is to administer (I) and (II) starting 4 days before and stopping 1 day before treatment with (A). (A) is then administered until remission is achieved and then (I) and (II) are again administered daily until 1-2 days before treatment with (A) is restarted. (I) and (II) are already known as antiinflammatories for treating arthritis and rheumatism, and as thrombocyte-aggregation inhibitors. They are now found to accelerate complete remission; to increase the time of remission; to maintain remission and to reduce toxicity towards non-cancerous blood marrow cells.
Malnutrition is a risk factor of sarcopenia in the elderly. During the COVID-19 pandemic, limited transportation and supply chain disruptions restricted access to nutritious foods. We assessed the nutritional status and sarcopenia risk in older people living with HIV (PLWH) on combination antiretroviral therapy in Thailand. This study was a hospital-based cohort among virally suppressed older PLWH who came for routine HIV clinic visits. The mini nutritional assessment (MNA), body composition analysis and 5-time chair stand test (CST) were performed to assess the nutritional status, muscle mass and physical performance, respectively. A total of 177 PLWH were enrolled (57.60% male). The median age was 58 years (IQR 55-62 years). Thirty-five participants (19.8%) were at risk of developing sarcopenia, and 28.2% had abnormal nutritional status. Muscle mass correlated positively with nutritional scores (r = 0.355, p < 0.001) but negatively with 5-time CST duration (r = -0.173, p = 0.021). In the multivariate model, muscle mass was associated with age, sex, mid-arm circumference, calf circumference and 5-time CST duration. In a well-viral-suppressed older Asian PLWH cohort, given the positive correlation between nutritional status and muscle mass, the nutritional status of older PLWH should be routinely evaluated and monitored.
The clinical trial will follow a two period acute double-blind cross-over design. It will take place at Richardson Centre for Functional Food and Nutraceuticals (RCFFN) at University of Manitoba, Winnipeg, Canada.

The trial will recruit healthy adult participants. Participants will consent to participate in two acute feeding sessions. Participants will be randomized to either control (low avenanthramides) then treatment (high avenanthramides) or treatment then control. Participants will arrive at the study center fasted between 8 and 10:30 am on the session days. They will be provided either the study treatment or control product based on randomization sequence for their first study visit. Baseline blood glucose (0 min) will be measured in duplicate via finger stick blood sample right before their first bite of the treatment product, and at 15, 30, 45, 60, 90 and 120 mins after baseline. The timer will be started when they take their first bite. During the second visit participant will consume the other treatment based on the randomization (the oatmeal that they didn't receive in their first visit and follow exactly the same procedure as the first visit). There will be a minimum of 5 days between sessions. Female participants will be scheduled during the luteal phase of their menstruation cycle. There will be a maximum of 8 weeks between the two sessions, therefore, participants will finish the both sessions within an 8 week period.
The trial is a non-randomized, open-label, dose escalation phase I/II clinical trial. A total of 12 participants will be enrolled - patients will be treated in cohorts of 3 to determine the safety and preliminary efficacy of autologous, ex-vivo expanded bone-marrow derived MSC injected into the knee joint in patients with moderate to advanced knee osteoarthritis.

A minimum of three evaluable patients will be entered at each dose level until the maximum tolerated dose (MTD) is reached. Toxicity will be evaluated and graded according to the Common Terminology Criteria (CTC) for Adverse Events, as Grade 3-4. If a patient is discontinued due to a grade 3 or 4 adverse event (i.e. dose-limiting toxicity, DLT), an additional patient will be enrolled at the same dose level to ensure that a minimum of 3 patients are evaluated. If 0/3 patients experience dose-limiting (DLT) at a given dose level, then the dose will be escalated for next cohort of 3 patients. If 1/3 patients experience DLT at a given dose level, then an additional 3 patients will be treated at that dose level. If no other patient experiences a DLT, dose escalation will continue. If DLT occurs in 2/3 or 2/6 patients, dose escalation will stop and the prior dose level will be declared the MTD for the MSC cell infusions in this study.
BACKGROUND: More than half of Chinese older adults over 60 are suffering from hearing loss, which might increase the risk of depression. Outdoor activity engagement is a key factor to alleviate depression symptoms. This study is conducted to analyze the associations between hearing loss and depression, and explore the role of outdoor activity engagement on depression.
METHODS: This study was based on the Chinese Longitudinal Healthy Longevity Survey (CLHLS), which collected the health and demographic information of elderly people in 23 provinces in China. In total, 12,333 older adults over 60 were recruited in the final analysis. Participants' risk of depressive symptoms was assessed using the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10). The relationship between self-reported hearing loss and depression in older adults was tested using logistic regression models.
RESULTS: The findings suggested a significant relationship between self-reported hearing loss and depressive symptoms (OR = 1.513, 95%CI = 1.391-1.646, P < 0.001). In addition, outdoor activity engagement have a moderation effect on self-reported hearing loss, among which entertainment and physical activities can better reduce the risk of depression.
CONCLUSION: Evidence from this study suggests that older adults with self-reported hearing loss can perform appropriate outdoor activities. Early recognition and intervention in hearing loss may reduce the risk of depression.
PROBLEM TO BE SOLVED: To inhibit Helicobacter by administering a 8-16C fatty acid monoglyceride or a 12C fatty acid or lauric acid. SOLUTION: At least one monoglyceride of a 8-16C fatty acid (e. g. mono caprin) or lauric acid or a liberated 12C fatty acid is administered in the form of a nutrient composition. The active amount of the monoglyceride is 0.001-4.3 g, preferably 0.003-2.5 g/kg/day based on 1 kg weight daily. The standard amount of the monoglyceride in the nutrient composition is 0.05-10 g, preferably 0.2-6 g based on 100 calories of the composition. The composition contains artificial nutrient for infant or a fat-soluble artificial nutrient for adult and child. Since Helicobacter causes gastric injuries such as indigestion, ulcer and cancer, the composition inhibits growth of Helicobacter by control, destruction and suppression.